Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis

Serge J. Zweers, Alexey Shiryaev, Mina Komuta, Mette Vesterhus, Johannes R. Hov, Maria J. Perugorria, D. Rudi de Waart, Jung-Chin Chang, Shanna Tol, Anje A. te Velde, Wouter J. de Jonge, Jesus M. Banales, Tania Roskams, Ulrich Beuers, Tom H. Karlsen, Peter L. Jansen, Frank G. Schaap

Research output: Contribution to journalArticleAcademicpeer-review

35 Citations (Scopus)

Abstract

To better understand the pathogenesis of primary sclerosing cholangitis, anti- and pro-inflammatory factors were studied in bile. Ductal bile of PSC patients (n = 36) and controls (n = 20) was collected by endoscopic retrograde cholangiography. Gallbladder bile was collected at liver transplantation. Bile samples were analysed for cytokines, FGF19 and biliary lipids. Hepatobiliary tissues of PSC and non-PSC patients (n = 8-11 per patient group) were collected at transplantation and were analysed for IL8 and FGF19 mRNA expression and IL8 localization. The effect of IL8 on proliferation of primary human cholangiocytes and expression of pro-fibrotic genes was studied. In PSC patients, median IL8 in ductal bile was 6.6 ng/ml vs. 0.24 ng/ml in controls. Median IL8 in gallbladder bile was 7.6 ng/ml in PSC vs. 2.2 and 0.3 ng/ml in two control groups. IL8 mRNA in PSC gallbladder was increased and bile ducts stained positive for IL8. In vitro, IL8 induced proliferation of primary human cholangiocytes and increased the expression of pro-fibrotic genes. Elevation of IL8 in bile of PSC patients, collected at different stages of disease, indicates an ongoing inflammatory stimulus that drives IL8 production. This challenges the idea that advanced PSC is a burned-out disease, and calls for reconsideration of anti-inflammatory therapy in PSC
Original languageEnglish
Pages (from-to)1370-1377
JournalLiver international
Volume36
Issue number9
DOIs
Publication statusPublished - 2016

Cite this